Marker Therapeutics, Inc.
Viés de alta

Marker Therapeutics Receives FDA Orphan Drug Designation for its

MRKR: Marker Therapeutics, Inc.
2020-04-29 16:05:00
Marker Therapeutics Receives FDA Orphan Drug Designation for its Multi-Antigen Targeted T Cell Therapy for Acute Myeloid Leukemia

Aviso legal